



BioLight Life Sciences Ltd.

(the "Company")

February 5, 2025

To: Israel Security Authority
www.isa.gov.il

TASE Tel Aviv Stock Exchange
www.tase.co.il

Re: SANOCULIS (Portfolio company) - Notice of Distribution Agreement Termination

The Company hereby updates that it was informed on February 4, 2025, by Sanoculis Ltd.[1] ("Sanoculis"), a portfolio company, that Bausch + Lomb Corporation ("Bausch + Lomb") notified Sanoculis of the termination of their exclusive distribution agreement in Europe, effective 180 days from the date of notice (i.e., July 24, 2025). The distribution agreement is part of an integrated strategic transaction signed in July 2022 between Sanoculis and Bausch + Lomb, which included an investment agreement under which an investment round of approximately \$17 million was completed in Sanoculis with Bausch + Lomb's participation, an exclusive 5-year distribution agreement for Sanoculis products in Europe by Bausch + Lomb, and an option agreement for Bausch + Lomb to acquire all of Sanoculis' assets, which expired at the end of October 2024[2].

Following the option expiration and the expected termination of the distribution agreement as mentioned above, as reported to the Company by Sanoculis, Sanoculis is exploring alternatives for engaging with other strategic players and/or alternative distributors in Europe. It should be noted that there is no certainty that Sanoculis' actions will materialize into binding agreements.

About Sanoculis

Sanoculis develops a minimally invasive surgical medical device for glaucoma surgeries and/or combined surgery for glaucoma with cataract surgery.

As reported to the Company, Sanoculis continues its global commercial activity to market the Sanoculis product in Europe through Bausch + Lomb until the end of the distribution agreement period, and in Israel through a local distributor in accordance with CE approvals for marketing in Europe and AMAR approval for marketing in Israel for the product's main existing indication (Moderate to Severe Glaucoma) and an additional product indication (Severe Glaucoma).

***Forward-looking information** - The information, details, and assessments of the company and Sanoculis included in this section regarding the examination of alternatives for engagement with other strategic players and/or alternative distributors in Europe (if at all), as well as continued product marketing according to the aforementioned indications, constitute "forward-looking information" as defined in the Securities Law, 1968, which involves high uncertainty and is based, among other things, on third parties and many variables over which the company and/or Sanoculis may not necessarily have control, and therefore the information, details and assessments as stated may not materialize and/or may not fully materialize and/or may materialize in a materially different manner than initially assessed or anticipated.*

About the Company

The Company holds and invests in companies ("Portfolio Companies") in the field of eye diseases and treatments through investment, management, development, and commercialization of projects and technologies and/or products in the fields of advanced medical devices, drugs, diagnostics, and digital medicine in the eye field (together - "Eye Products"), which aim to address real needs in the field of eye diseases and treatments. The Portfolio Companies and their various Eye Products are at different developmental, clinical (or pre-clinical), and commercial stages, ranging from initial development to sales.

Sincerely,

BioLight Life Sciences Ltd.

[1] As of this date, the company holds approximately 5% of Sanoculis' issued and outstanding share capital (approximately 4.4% on a fully diluted basis). For additional details about Sanoculis, see Section 4.8 of Chapter A (Description of Corporation Business) in the company's annual report published on March 21, 2024 [Reference No.: 2024-01-024910], concise business update and voluntary financial information for the first quarter ended March 31, 2024, published on May 23, 2024 [Reference No.: 2024-01-053544], Section 4.7 of the company's semi-annual report for 2024 published on August 21, 2024 [Reference No.: 2024-01-085902], and concise business update and voluntary financial information for the third quarter ended September 30, 2024, published on November 24, 2024 [Reference No.: 2024-01-618226], included herein by reference.

[2] For additional details, see the company's immediate report dated November 4, 2024 [Reference No.: 2024-01-613519] included herein by reference.